Chemical Biology and Drug Design

MARCH 3, 2024

Study on the mechanism of graph Qufeng Tongqiao Prescription in the treatment of cerebral ischemia through network pharmacology combined with animal experiments. Abstract To explore the of Qufeng Tongqiao Prescription in the treatment of cerebral ischemia–reperfusion (CIR) and associated molecular network mechanism. Venny diagram, gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) analysis, protein–protein interaction (PPI), hub genes mining, molecular docking, combined with a

Treatment 100

Treatment Research 100

FDA Law Blog: Biosimilars

MARCH 3, 2024

By Steven J. Gonzalez & JP Ellison — The most recent version of the BIOSECURE Act (the “Act”) was introduced in the U.S. House of Representatives ( H.B. 7085 ) and Senate ( S.B. 3558 ) on January 25, 2024. This proposed legislation should be of interest to any biotechnology companies that want to do business with the federal government in the future.

Government 102

Government Small Molecule FDA Approval Regulations 102

Drug Patent Watch

MARCH 3, 2024

This chart shows the drugs with the most patents in Ukraine. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… The post Which pharmaceutical drugs have the most drug patents in Ukraine? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceuticals 104

Pharmaceuticals Drugs 104

FDA Law Blog: Biosimilars

MARCH 3, 2024

By Jeffrey N. Gibbs & Allyson B. Mullen — FDA’s proposed rule to regulate laboratory developed tests (LDTs) as devices took one more step towards being finalized – and to a likely judicial showdown. On March 1, the Office of Management and Budget (OMB) received the draft final LDT rule for review ( here ). The LDT rule has moved forward with astonishing speed, advancing from the release of the proposed rule on October 3, 2023 to OMB in less than five months.

Laboratories 64

Laboratories Regulations FDA Government 64

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Codon

MARCH 3, 2024

Alexander von Humboldt relaxes in his library. Looks like a nice place! Asimov Press has now existed for two months. ( Woo! ) We’re publishing an essay at a pace of roughly one per week, and our first printed compilation will be available in May. But there are only two of us (Niko & Xander), and our pile of essay ideas has already swelled to 450+ rows in a spreadsheet.

DNA 89

DNA Engineering Vaccine Virus 89